Corporate & Securities Law

The attorneys at Eccleston Law have launched an investigation into Resverlogix Corporation, a Canadian biotechnology company that is publicly traded on the Toronto Stock Exchange (TSX: RVX). 

According to its website,  Resverlogix is ?focused on developing novel therapies for unmet medical markets, primarily cardiovascular disease (CVD), cancer and fibrotic conditions. Our goal is to improve the quality and longevity of patient?s lives by becoming a leader in the research, development and commercialization of innovative products for these grievous diseases.?  Eccleston Law believes that shares of Resverlogix might have been included a US-based private equity fund known as the Premier Equity Fund. 

Eccleston Law represents individual and institutional investors to recover their investment losses caused by securities and investment fraud. Our attorneys also help victims of Ponzi schemes pursue recovery by submitting claims with receiverships established by the SEC or by assisting victims with the filing of a Theft Loss Tax Deduction with the IRS.

If you are a investor residing in the United States that invested in Resverlogix or in the Premier Equity Fund, or if you have information about a private placement securities offering involving Resverlogix, please contact Jim Eccleston at the Eccleston Law Offices at 312-332-0000.